A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Everolimus represents an approved therapy for patients with advanced well/moderately
differentiated pancreatic NETs. Although some patients could benefit from this drug in terms
of long-term tumor growth control, others are resistant upfront or become resistant during
treatment. Therefore, it is crucial to detect some biological factors which can help to
identify the responsive tumors. Given that Everolimus is a biological agent and its mechanism
of action can be partially directed towards angiogenesis its effects can be studied on
different levels and with different methods. Upfront and early surrogate predictive markers
of activity/efficacy can be studied on tumor tissue, tumor imaging, and peripheral blood.
mTOR pathways alterations, circulating endothelial cells, and other circulating angoigenic
factors will be correlated with clinical outcome. Tumor perfusion and circulating markers
will be studied also as markers of response compared with the morphological imaging.